5-HT1A Inhibitors
2 drugsAbout 5-HT1A
The 5-HT1A receptor is a G protein-coupled receptor (GPCR) that modulates serotonergic neurotransmission in the central nervous system (CNS). It plays a crucial role in mood regulation and anxiety.
The 5-HT1A receptor is a drug target for various CNS disorders; however, there is currently no genetic evidence directly linking it to specific diseases.
Two FDA-approved drugs target 5-HT1A, including VIIBRYD (vilazodone hydrochloride). Both drugs are small molecules and are indicated for CNS conditions.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
Top 5-HT1A Drugs
The competitive landscape includes two companies with approved drugs: Alembic and AbbVie.
Low market concentration suggests relatively low barriers to entry for new competitors.
5-HT1A Drug Modality Landscape
Modalities
Routes of Administration
5-HT1A is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore opportunities for novel modalities like antibodies or biologics to differentiate from existing therapies.
5-HT1A Clinical Trials 20 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 5 | 3 | 0 | 2 | 100% |
| Phase 3 | 7 | 7 | 0 | 0 | 100% |
| Phase 4 | 8 | 6 | 2 | 0 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
5-HT1A Drug Approval Timeline (2011 - 2024)
The first drug was approved in 2011, and the most recent in 2019, spanning a 9-year period.
The recent approval suggests continued interest, but a longer gap may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (9 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 11 clinical trials targeting 5-HT1A.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities